What Is Tesamorelin? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Tesamorelin is an FDA-approved prescription medication for a specific use under Egrifta products. It is not a general weight-loss medication, and unapproved tesamorelin products sold online may carry safety, quality, and legal risks.
Quick answer
Tesamorelin is a synthetic growth hormone-releasing hormone analog, also called a growth hormone-releasing factor analog. It stimulates the pituitary gland to release endogenous growth hormone. In the United States, tesamorelin is FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV and lipodystrophy. It is not indicated for general weight loss or obesity treatment. Human clinical trials support its use for HIV-associated abdominal lipodystrophy, but it can raise IGF-1, cause fluid retention, injection-site reactions, glucose-related effects, and other side effects. Tesamorelin is prohibited in competitive sport under WADA rules.
Key facts about Tesamorelin
| Question | Answer |
|---|---|
| What is tesamorelin? | A synthetic growth hormone-releasing hormone analog. |
| Brand names | Egrifta SV, Egrifta WR. |
| Drug class | Growth hormone-releasing factor analog / GHRH analog. |
| Main mechanism | Stimulates pituitary cells to produce and release endogenous growth hormone. |
| FDA-approved? | Yes, under Egrifta products for a specific indication. |
| Approved use | Reduction of excess abdominal fat in adults with HIV and lipodystrophy. |
| Not indicated for | General weight loss management, obesity treatment, or athletic/bodybuilding performance. |
| Human evidence level | Strong human evidence for HIV-associated abdominal lipodystrophy. |
| Common side effects | Injection-site reactions, joint pain, extremity pain, muscle pain, nausea, vomiting, rash, itching, and fluid-retention symptoms. |
| Main safety concern | Elevated IGF-1, neoplasm risk considerations, glucose intolerance/diabetes risk, fluid retention, hypersensitivity, and use outside the approved population. |
| Sports status | Prohibited by WADA as a growth hormone-releasing factor. |
What is tesamorelin?
Tesamorelin is a prescription growth hormone-releasing hormone analog. It is designed to stimulate the pituitary gland to release the body’s own growth hormone.
The Mayo Clinic drug reference describes tesamorelin as a hormone similar to one normally released from the hypothalamus and says it is used to reduce excess stomach-area fat in patients with HIV infection.
In the United States, tesamorelin is sold as:
| Brand | Active ingredient | Main FDA-approved use |
|---|---|---|
| Egrifta SV | Tesamorelin | Reduction of excess abdominal fat in adults with HIV and lipodystrophy. |
| Egrifta WR | Tesamorelin | Reduction of excess abdominal fat in adults with HIV and lipodystrophy. |
The Egrifta WR prescribing information states that Egrifta WR is indicated for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy. It also says Egrifta WR and Egrifta SV are not substitutable because the formulations and strengths differ.
The key distinction:
Tesamorelin is an FDA-approved medication for HIV-associated abdominal lipodystrophy. It is not an FDA-approved general belly-fat, obesity, bodybuilding, or anti-aging peptide.
How does tesamorelin work?
Tesamorelin acts like growth hormone-releasing hormone, also called GHRH or growth hormone-releasing factor.
It stimulates pituitary somatotroph cells to produce and release endogenous growth hormone. Growth hormone can then affect fat metabolism and increase insulin-like growth factor 1, also called IGF-1.
The Egrifta SV prescribing information describes Egrifta SV as a growth hormone-releasing factor analog. The label also states that the exact mechanism by which tesamorelin reduces visceral adipose tissue is not known.
In plain English:
Tesamorelin does not directly supply human growth hormone. It signals the body to release more of its own growth hormone, which can reduce visceral abdominal fat in the approved HIV-lipodystrophy population.
Mechanism is not proof for every claim. Tesamorelin’s approved use is specific, and claims about general fat loss, anti-aging, muscle gain, or athletic recovery go beyond the FDA-approved indication.
What is tesamorelin used for?
Tesamorelin has a specific FDA-approved use and many broader online claims. These should not be treated the same.
| Use | Evidence level | What is known | What is not known |
|---|---|---|---|
| HIV-associated abdominal lipodystrophy | Strong human evidence | Egrifta SV and Egrifta WR are FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. | Long-term cardiovascular safety has not been established. |
| General weight loss | Not indicated | The label says Egrifta products are not indicated for weight loss management. | It should not be treated as a general obesity or weight-loss medication. |
| Obesity treatment | Not indicated | Tesamorelin is not FDA-approved to treat obesity. | Safety and efficacy for general obesity are not established under the label. |
| Anti-aging | Unsupported | Often marketed by peptide clinics. | Anti-aging and longevity benefits are not proven. |
| Muscle gain/body recomposition | Weak / extrapolated | GH biology may influence body composition. | Not established as a safe or approved performance/bodybuilding treatment. |
| Liver fat in HIV | Clinical research evidence | Studies have evaluated liver-fat reductions in people with HIV and abdominal fat accumulation. | Approved indication remains excess abdominal fat in HIV lipodystrophy. |
| Online tesamorelin products | High uncertainty | Sellers may market it as a peptide product. | Quality, sterility, dosing, identity, and legal status may be unknown. |
What does the research show?
Human evidence for HIV-associated abdominal fat
Tesamorelin has strong human clinical evidence for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy.
A PubMed-indexed pooled analysis of two phase 3 studies evaluated tesamorelin in antiretroviral-treated HIV patients with excess abdominal fat. The study found reductions in visceral adipose tissue and supported tesamorelin’s clinical development for this indication.
A PubMed review of tesamorelin in HIV-associated lipodystrophy concluded that tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26 to 52 weeks of treatment.
The practical interpretation:
Tesamorelin has real human clinical evidence for reducing excess abdominal fat in adults with HIV and lipodystrophy. This is not just a preclinical peptide claim.
Human evidence for liver fat in HIV
Tesamorelin has also been studied for liver fat and metabolic outcomes in people with HIV.
A PubMed-indexed study on visceral fat and liver fat found that tesamorelin administered for 6 months was associated with reductions in visceral fat and modest reductions in liver fat.
The practical interpretation:
Tesamorelin may have metabolic effects beyond visible abdominal fat, but the approved use is still specific to excess abdominal fat in adults with HIV and lipodystrophy.
Evidence limitations
The evidence does not support treating tesamorelin as a general-purpose fat-loss drug.
The MedlinePlus drug information page says tesamorelin injection is used to decrease extra stomach-area fat in adults with HIV who have lipodystrophy and explicitly says it is not used to help with weight loss.
The practical interpretation:
Tesamorelin is not the same category as semaglutide or tirzepatide. It is not an FDA-approved chronic weight-management medication.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Tesamorelin reduces excess abdominal fat in adults with HIV and lipodystrophy.” | Supported | This is the FDA-approved indication for Egrifta products. |
| “Tesamorelin is FDA-approved.” | Supported for a specific use | It is approved as Egrifta products for reduction of excess abdominal fat in adults with HIV and lipodystrophy. |
| “Tesamorelin is a general weight-loss drug.” | False | Egrifta labels and MedlinePlus state it is not indicated/used for weight-loss management. |
| “Tesamorelin treats obesity.” | Unsupported as an approved claim | It is not FDA-approved as an obesity medication. |
| “Tesamorelin reduces liver fat.” | Supported in clinical research context | Studies show modest liver-fat reduction in people with HIV, but that is not the same as a broad approved liver-disease indication. |
| “Tesamorelin builds muscle.” | Weak / extrapolated | Online claims often extrapolate from GH biology, not approved clinical outcomes. |
| “Tesamorelin is an anti-aging peptide.” | Unsupported | Anti-aging and longevity claims are not established. |
| “Tesamorelin is allowed for athletes.” | False | WADA bans tesamorelin and related growth hormone-releasing factors. |
| “Research-use tesamorelin is the same as Egrifta.” | Misleading | FDA-approved Egrifta products have regulated manufacturing, labeling, and prescribing controls. |
Is tesamorelin FDA-approved?
Yes. Tesamorelin is FDA-approved under Egrifta products for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy.
The Egrifta WR prescribing information states that Egrifta WR is indicated for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label also states that Egrifta WR is not indicated for weight loss management and that Egrifta WR and Egrifta SV are not substitutable.
The Egrifta SV prescribing information similarly states that Egrifta SV is indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy and is not indicated for weight loss management.
The key distinction:
Tesamorelin is FDA-approved for HIV-associated abdominal lipodystrophy, not for general weight loss, obesity, bodybuilding, or anti-aging.
Is tesamorelin legal?
Tesamorelin is legal when prescribed and dispensed as an FDA-approved medication for the approved indication or otherwise used under appropriate medical/legal rules.
The problem is the online peptide market.
Some sellers market tesamorelin as a research peptide, bodybuilding peptide, or general body-composition peptide. That does not make it equivalent to FDA-approved Egrifta SV or Egrifta WR.
The blunt version:
Prescription Egrifta from a legitimate pharmacy is different from “research use only” tesamorelin sold online.
Is tesamorelin banned in sports?
Yes. Tesamorelin is prohibited in sport.
WADA has identified tesamorelin among banned growth hormone-releasing hormone analogs. A WADA-funded tesamorelin detection study page states that tesamorelin and related compounds are banned by WADA at all times.
Older WADA prohibited-list documents also list tesamorelin by name among growth hormone-releasing factors. The WADA Prohibited List is updated annually, so athletes should always check the current list and Global DRO.
For athletes, the answer is simple:
Do not use tesamorelin if you are subject to anti-doping rules unless an official therapeutic-use process confirms otherwise.
Safety and side effects
Tesamorelin has real clinical evidence, but it also has real safety considerations.
Common or important side effects and risks may include:
- Injection-site reactions
- Joint pain
- Extremity pain
- Muscle pain
- Nausea
- Vomiting
- Rash
- Itching
- Fluid retention
- Edema
- Carpal tunnel syndrome
- Elevated IGF-1
- Glucose intolerance or diabetes-related concerns
- Hypersensitivity reactions
The Egrifta WR prescribing information warns about increased risk of neoplasms, elevated IGF-1, fluid retention, hypersensitivity reactions, and glucose intolerance or diabetes mellitus. It also states that the long-term cardiovascular safety of Egrifta WR has not been established.
Important contraindications include:
- Pituitary gland tumor or pituitary-related problems
- Active malignancy
- Hypersensitivity to tesamorelin or product ingredients
- Pregnancy
- Use in pediatric patients
A serious evaluation of tesamorelin should separate FDA-approved Egrifta products from online peptide products.
Tesamorelin vs similar peptides
| Compound | Category | Main difference |
|---|---|---|
| Tesamorelin | GHRH analog | FDA-approved as Egrifta products for excess abdominal fat in adults with HIV and lipodystrophy. |
| Sermorelin | GHRH analog | Historically FDA-approved as Geref, now discontinued; not the same as tesamorelin. |
| CJC-1295 | GHRH analog | Long-acting GHRH analog; not FDA-approved and prohibited in sport. |
| Ipamorelin | Growth hormone secretagogue | Works through ghrelin receptor pathways, not GHRH receptor pathways. |
| Human growth hormone | Recombinant hormone | Supplies growth hormone directly rather than stimulating endogenous release. |
| Semaglutide | GLP-1 receptor agonist | FDA-approved metabolic drug for diabetes/weight-related indications, not a GHRH analog. |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | FDA-approved metabolic drug, not a growth hormone-releasing factor. |
The key distinction:
Tesamorelin is a GHRH analog with a specific FDA-approved HIV-lipodystrophy use. It is not the same type of drug as GLP-1 medications or tissue-repair peptides.
Why is tesamorelin sold as “research use only”?
Some online sellers use “research use only” language to sell tesamorelin outside normal prescription-drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Egrifta SV | FDA-approved tesamorelin product for excess abdominal fat in adults with HIV and lipodystrophy. |
| Egrifta WR | FDA-approved tesamorelin product for the same indication, but not substitutable with Egrifta SV. |
| Compounded tesamorelin | Not the same as FDA-approved Egrifta products and should be evaluated carefully. |
| Research-use tesamorelin | Not an FDA-approved consumer therapeutic product. |
| Online peptide tesamorelin | Higher risk for identity, sterility, dosing, and quality problems. |
How to evaluate tesamorelin claims online
| Claim | What to verify |
|---|---|
| “FDA-approved tesamorelin” | Is it actually Egrifta SV or Egrifta WR, or an unapproved peptide product? |
| “For belly fat” | The approved use is excess abdominal fat in adults with HIV and lipodystrophy, not general belly fat. |
| “Weight-loss peptide” | False as an approved claim. Egrifta products are not indicated for weight loss management. |
| “Bodybuilding peptide” | Unsupported and high-risk for athletes because tesamorelin is prohibited in sport. |
| “Anti-aging peptide” | Unsupported by strong clinical evidence. |
| “Same as Egrifta” | FDA-approved Egrifta products have specific manufacturing, quality, labeling, and prescribing controls. |
| “Research use only” | This does not mean safe, approved, legal, or appropriate for human use. |
| “No side effects” | False. Tesamorelin has known warnings and side effects. |
Bottom line
Tesamorelin is a synthetic growth hormone-releasing hormone analog and an FDA-approved prescription medication when used as Egrifta SV or Egrifta WR for reducing excess abdominal fat in adults with HIV and lipodystrophy. It has strong human clinical evidence for that specific indication, but it is not a general weight-loss drug, obesity medication, bodybuilding peptide, or anti-aging treatment.
The most defensible conclusion is:
Tesamorelin is legitimate as an FDA-approved drug for a narrow HIV-lipodystrophy use case, but online claims about general fat loss, body recomposition, anti-aging, and performance often go beyond the evidence. Athletes should avoid it because tesamorelin is prohibited in sport.
FAQ
What is tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone analog. It stimulates the pituitary gland to release endogenous growth hormone.
What is tesamorelin used for?
Tesamorelin is FDA-approved under Egrifta products to reduce excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin FDA-approved?
Yes. Tesamorelin is FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin a weight-loss drug?
No. Egrifta products are not indicated for weight loss management. Tesamorelin should not be treated as a general obesity or weight-loss medication.
Is tesamorelin the same as Egrifta?
Tesamorelin is the active ingredient. Egrifta SV and Egrifta WR are FDA-approved brand-name products containing tesamorelin.
Are Egrifta SV and Egrifta WR interchangeable?
No. The Egrifta WR label says Egrifta WR and Egrifta SV are not substitutable because their formulations, strengths, dosing, reconstitution instructions, and storage requirements differ.
Is tesamorelin the same as sermorelin?
No. Both are GHRH analogs, but they are different substances with different FDA histories and clinical uses.
Is tesamorelin the same as CJC-1295?
No. Tesamorelin is FDA-approved for HIV-associated abdominal lipodystrophy under Egrifta products. CJC-1295 is not FDA-approved.
Does tesamorelin build muscle?
Muscle-building claims are not an approved use. Tesamorelin may influence growth-hormone pathways, but that does not prove it is a safe or approved muscle-building treatment.
Is tesamorelin safe?
Tesamorelin is FDA-approved for a specific use but is not risk-free. Important concerns include elevated IGF-1, glucose intolerance, fluid retention, hypersensitivity, neoplasm risk considerations, and unknown long-term cardiovascular safety.
Is tesamorelin banned in sports?
Yes. Tesamorelin is prohibited by WADA as a growth hormone-releasing factor.
What is the biggest risk with tesamorelin?
The biggest risks are using it outside the approved HIV-lipodystrophy indication, confusing online research-use products with FDA-approved Egrifta, and using it despite anti-doping rules or medical contraindications.
Sources
- FDA: Egrifta WR Prescribing Information
- FDA: Egrifta SV Prescribing Information
- Mayo Clinic: Tesamorelin Subcutaneous Route Description
- MedlinePlus: Tesamorelin Injection
- Cleveland Clinic: Tesamorelin Injection
- PubMed: Effects of Tesamorelin in ART-Treated HIV Patients with Excess Abdominal Fat
- PubMed: Tesamorelin Review in HIV-Associated Lipodystrophy
- PubMed: Effect of Tesamorelin on Visceral Fat and Liver Fat
- NCBI Bookshelf: Clinical Review Report, Tesamorelin Egrifta
- WADA: Tesamorelin Administration Study
- WADA: Prohibited List
Frequently asked questions
What is tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone analog. It stimulates the pituitary gland to release endogenous growth hormone.
What is tesamorelin used for?
Tesamorelin is FDA-approved under Egrifta products to reduce excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin FDA-approved?
Yes. Tesamorelin is FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin a weight-loss drug?
No. Egrifta products are not indicated for weight loss management. Tesamorelin should not be treated as a general obesity or weight-loss medication.
Are Egrifta SV and Egrifta WR interchangeable?
No. The Egrifta WR label says Egrifta WR and Egrifta SV are not substitutable because their formulations, strengths, dosing, reconstitution instructions, and storage requirements differ.
Is tesamorelin banned in sports?
Yes. Tesamorelin is prohibited by WADA as a growth hormone-releasing factor.
Sources
- [1]FDA: Egrifta WR Prescribing Information
Prescribing Information
- [2]FDA: Egrifta SV Prescribing Information
Prescribing Information
- [3]Mayo Clinic: Tesamorelin Subcutaneous Route Description
Medical Reference
- [4]MedlinePlus: Tesamorelin Injection
Medical Reference
- [5]Cleveland Clinic: Tesamorelin Injection
Medical Reference
- [6]
- [7]
- [8]
- [9]NCBI Bookshelf: Clinical Review Report, Tesamorelin Egrifta
Clinical Review
- [10]WADA: Tesamorelin Administration Study
Anti Doping
- [11]WADA: Prohibited List
Anti Doping
Last updated May 9, 2026